<unk>  is a CD20-directed cytolytic antibody that is FDA approved for the treatment of relapsing or primary progressive forms of multiple sclerosis.   Common adverse reactions include upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.
Ocrelizumab
Risankizumab
Ibalizumab
Atezolizumab
Efalizumab
Tocilizumab
Emicizumab
Abatacept